507 related articles for article (PubMed ID: 25981803)
1. Radiosensitivity enhancement of radioresistant glioblastoma by epidermal growth factor receptor antibody-conjugated iron-oxide nanoparticles.
Bouras A; Kaluzova M; Hadjipanayis CG
J Neurooncol; 2015 Aug; 124(1):13-22. PubMed ID: 25981803
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles.
Kaluzova M; Bouras A; Machaidze R; Hadjipanayis CG
Oncotarget; 2015 Apr; 6(11):8788-806. PubMed ID: 25871395
[TBL] [Abstract][Full Text] [Related]
3. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma.
Hadjipanayis CG; Machaidze R; Kaluzova M; Wang L; Schuette AJ; Chen H; Wu X; Mao H
Cancer Res; 2010 Aug; 70(15):6303-12. PubMed ID: 20647323
[TBL] [Abstract][Full Text] [Related]
4. EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells.
Struve N; Riedel M; Schulte A; Rieckmann T; Grob TJ; Gal A; Rothkamm K; Lamszus K; Petersen C; Dikomey E; Kriegs M
Oncotarget; 2015 Oct; 6(32):33867-77. PubMed ID: 26418954
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles.
Norouzi M; Yathindranath V; Thliveris JA; Kopec BM; Siahaan TJ; Miller DW
Sci Rep; 2020 Jul; 10(1):11292. PubMed ID: 32647151
[TBL] [Abstract][Full Text] [Related]
6. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.
Ning S; Knox SJ
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):197-203. PubMed ID: 15337556
[TBL] [Abstract][Full Text] [Related]
7. Convection-enhanced delivery of cetuximab conjugated iron-oxide nanoparticles for treatment of spontaneous canine intracranial gliomas.
Freeman AC; Platt SR; Holmes S; Kent M; Robinson K; Howerth E; Eagleson J; Bouras A; Kaluzova M; Hadjipanayis CG
J Neurooncol; 2018 May; 137(3):653-663. PubMed ID: 29350351
[TBL] [Abstract][Full Text] [Related]
8. Glioblastoma Therapy Using Codelivery of Cisplatin and Glutathione Peroxidase Targeting siRNA from Iron Oxide Nanoparticles.
Zhang Y; Fu X; Jia J; Wikerholmen T; Xi K; Kong Y; Wang J; Chen H; Ma Y; Li Z; Wang C; Qi Q; Thorsen F; Wang J; Cui J; Li X; Ni S
ACS Appl Mater Interfaces; 2020 Sep; 12(39):43408-43421. PubMed ID: 32885649
[TBL] [Abstract][Full Text] [Related]
9. Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+PTEN-glioblastoma in vivo.
Xu W; Bi Y; Kong J; Zhang J; Wang B; Li K; Tian M; Pan X; Shi B; Gu J; Jiang H; Kong X; Li Z
Oncotarget; 2016 Apr; 7(17):24752-65. PubMed ID: 27029073
[TBL] [Abstract][Full Text] [Related]
10. EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma.
Mukherjee B; McEllin B; Camacho CV; Tomimatsu N; Sirasanagandala S; Nannepaga S; Hatanpaa KJ; Mickey B; Madden C; Maher E; Boothman DA; Furnari F; Cavenee WK; Bachoo RM; Burma S
Cancer Res; 2009 May; 69(10):4252-9. PubMed ID: 19435898
[TBL] [Abstract][Full Text] [Related]
11. Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma.
Zhang M; Kleber S; Röhrich M; Timke C; Han N; Tuettenberg J; Martin-Villalba A; Debus J; Peschke P; Wirkner U; Lahn M; Huber PE
Cancer Res; 2011 Dec; 71(23):7155-67. PubMed ID: 22006998
[TBL] [Abstract][Full Text] [Related]
12. Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo.
Eller JL; Longo SL; Kyle MM; Bassano D; Hicklin DJ; Canute GW
Neurosurgery; 2005; 56(1):155-62; discussion 162. PubMed ID: 15617598
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis.
Yang YP; Chang YL; Huang PI; Chiou GY; Tseng LM; Chiou SH; Chen MH; Chen MT; Shih YH; Chang CH; Hsu CC; Ma HI; Wang CT; Tsai LL; Yu CC; Chang CJ
J Cell Physiol; 2012 Mar; 227(3):976-93. PubMed ID: 21503893
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo.
Mamot C; Drummond DC; Noble CO; Kallab V; Guo Z; Hong K; Kirpotin DB; Park JW
Cancer Res; 2005 Dec; 65(24):11631-8. PubMed ID: 16357174
[TBL] [Abstract][Full Text] [Related]
15. STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma.
Geng L; Shinohara ET; Kim D; Tan J; Osusky K; Shyr Y; Hallahan DE
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):263-71. PubMed ID: 16274936
[TBL] [Abstract][Full Text] [Related]
16. Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model.
Kawakami K; Kawakami M; Kioi M; Husain SR; Puri RK
J Neurosurg; 2004 Dec; 101(6):1004-11. PubMed ID: 15597761
[TBL] [Abstract][Full Text] [Related]
17. PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment.
Cenciarelli C; Marei HE; Zonfrillo M; Pierimarchi P; Paldino E; Casalbore P; Felsani A; Vescovi AL; Maira G; Mangiola A
Mol Cancer; 2014 Nov; 13():247. PubMed ID: 25380967
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
[TBL] [Abstract][Full Text] [Related]
19. IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer.
Zhou H; Qian W; Uckun FM; Wang L; Wang YA; Chen H; Kooby D; Yu Q; Lipowska M; Staley CA; Mao H; Yang L
ACS Nano; 2015 Aug; 9(8):7976-91. PubMed ID: 26242412
[TBL] [Abstract][Full Text] [Related]
20. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.
Keir ST; Chandramohan V; Hemphill CD; Grandal MM; Melander MC; Pedersen MW; Horak ID; Kragh M; Desjardins A; Friedman HS; Bigner DD
J Neurooncol; 2018 Jul; 138(3):489-498. PubMed ID: 29564747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
